TG THERAPEUTICS, INC. Investment Income, Amortization of Discount
TG THERAPEUTICS, INC. (TGTX) reported Investment Income, Amortization of Discount of $331.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeAmortizationOfDiscount · last filed 2023-03-01
- TG THERAPEUTICS, INC. investment income, amortization of discount for the quarter ending 2020-12-31 was -$45.00K, a 193.75% decline year-over-year.
- TG THERAPEUTICS, INC. investment income, amortization of discount for the quarter ending 2020-09-30 was $6.00K, a 90.00% decline year-over-year.
- TG THERAPEUTICS, INC. investment income, amortization of discount for the quarter ending 2020-06-30 was $25.00K, a 66.22% decline year-over-year.
- TG THERAPEUTICS, INC. investment income, amortization of discount for the quarter ending 2020-03-31 was $44.00K, a 41.33% decline year-over-year.
- TG THERAPEUTICS, INC. investment income, amortization of discount for fiscal 2022 was $331.00K.
- TG THERAPEUTICS, INC. investment income, amortization of discount for fiscal 2020 was $30.00K, a 88.33% decline from fiscal 2019.
- TG THERAPEUTICS, INC. investment income, amortization of discount for fiscal 2019 was $257.00K, a 115.97% increase from fiscal 2018.
- TG THERAPEUTICS, INC. investment income, amortization of discount for fiscal 2018 was $119.00K.
| Period end | Investment Income, Amortization of Discount 3 month | Investment Income, Amortization of Discount 6 month | Investment Income, Amortization of Discount 9 month | Investment Income, Amortization of Discount 12 month |
|---|---|---|---|---|
| 2022-12-31 | $331.00K 10-K · filed 2023-03-01 | |||
| 2020-12-31 | -$45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$39.00K derived: sum of 2 quarters · filed 2023-03-01 | -$14.00K derived: sum of 3 quarters · filed 2023-03-01 | $30.00K 10-K · filed 2023-03-01 |
| 2020-09-30 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $31.00K derived: sum of 2 quarters · filed 2021-11-08 | $75.00K 10-Q · filed 2021-11-08 | $123.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $69.00K 10-Q · filed 2021-08-06 | $117.00K derived: sum of 3 quarters · filed 2022-03-01 | $177.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $44.00K 10-Q · filed 2021-05-10 | $92.00K derived: sum of 2 quarters · filed 2022-03-01 | $152.00K derived: sum of 3 quarters · filed 2022-03-01 | $226.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $108.00K derived: sum of 2 quarters · filed 2022-03-01 | $182.00K derived: sum of 3 quarters · filed 2022-03-01 | $257.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $134.00K derived: sum of 2 quarters · filed 2020-11-09 | $209.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $149.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $75.00K 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $119.00K 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |